Info on starting TRELEGY ELLIPTA

Incorporation of products, treatment

Significant revisions to Multiple Sclerosis chart to include different

Update of HIV chart with new products (canagliflozin)

bleeding risk than triple therapy, and appears

Some Highlights Include:









Total pages: 244 New pages: 42 New charts: 20

Changes: thousands. Charts updated daily, then to web/app.

NEW CHARTS

• Antibiotics: Oral & IV Expanded
  p. 81-85

• Antibiotics: Beta Lactam Allergy & Harms
  p. 86-87

• Antibiotics for Acute Otitis Media, Bronchitis, Pharyngitis, Sinusitis & Skin
  p. 88-98

• HIV (a complete overhaul)
  p. 105-106

• Community Acquired Pneumonia (CAP) Management
  p. 110-111

• Probiotics
  p. 113-114

• Cystitis- Uncomplicated
  p. 116-117

• Chronic Non-Cancer Pain (CNCP)
  p. 121-124

• Opioids: Prescribing Safety & Strategies
  p. 130-133

• Osteoporosis Chart (a complete overhaul)
  p. 137-138

• Rheumatoid Arthritis: DMARDS (additional 2 pages)
  p. 139-141

• Seizures: Antiepileptics (additional 2 pages)
  p. 155-158

• Cannabinoids (additional 2 pages)
  p. 199-201

• Dry Eye
  p. 213-214

• Substance Use Dx / Addiction / Stimulant Use Disorder
  p. 219-221

• Opioid Use Disorder
  p. 222-224

SCANNING THROUGH THE CHARTS

Some Highlights Include:

Go To...

Significant revisions to DAPT/TT chart: incorporation of major trials (PIONEER, AUGUSTUS, ENTRUST, TWILIGHT); dual therapy has less bleeding risk than triple therapy, and appears to be effective!

p.19-20

Incorporation of major SGLT-2 trials: CREDENCE, CANVAS (canagliflozin), DECLARE, DACA-HF (dapagliflozin).

p.40-42

Update of self-monitoring blood glucose monitors and insulin pens, highlighting unique features of each product.

p.43-44

Update of HIV chart with new products (JULUCA, DOVATO), drug coverage, safety information and more.

p.105-106

Expansion of seizure chart to include overview, clinical pearls, approach to treatment and more. (including pregnancy section)

p.155-158

Significant revisions to Multiple Sclerosis chart to include different products, treatment of disabling relapse and more.

p.148

Update of information based on guidelines and recommendations and addition of new BRANDS in Over-The-Counter chart.

p.171-174

Incorporation of AAP, NICE guidelines and recommendations in ADHD chart; stimulants are recommended 1st line for <6yr.s.

p.175-176

Incorporation of SYGMA1/2 trial in Asthma chart, outlining the use of LABA/ICS given only pm for mild asthma.

p.191-192

Incorporation of FLAME-IMPACT trial on new COPD pathways; new TRELEGY ELLIPTA; use of N-acetylcysteine in COPD chart.

p.193-194

Info on starting SUBOXONE, including both conventional & microdosing approaches; new SUBLOCALE and PROBUPHINE; considerations for pain management in Opioid Use Disorder chart.

p.222-224

PRICE CHANGES

Significant >10% price decrease:

• NITRO-DUR (all strengths): -30% to $4-14 less/month

Significant >10% price increase:

• IBAVIR (all strengths): +50% up to $785 more/month

Moderate 5-10% price increase:

• Oral Contraceptive Pills TRI-CYCLEN, TRI-CYCLEN LO, CYCLEN: +9% to $20-30 more/month

• TYLENOL with codeine #2, #3, #4: +9% to $3-7 more/month

• CONCERTA (most strengths): +5% to $4-6 more/month

• ZYPREXA, ZYPREXA ZYDIS (all strengths): +5% to $3-17 more/month

NEW DRUG (BRAND NAME) ADDITIONS

ADDYI, ADLYXINE, AIMOVIG, AKYNZEO, BELSOMRA, BITKARVY, CONTRAVE, CRESEMBA, DELSTRIGO, EVENITY, FASENRA, JULLUC, MAVENCAD, MEZERA, MONOFERRIC, MOAPO, OLUMIANT, ONSTRY, ORILISSA, OXANAX, OZEMPIC, PROBUPHINE, SILIQ, SOLIQUA, STEGDUAN, SYRIZI, TRELEGY ELLIPTA, TRUMENBA, VYZULTA, VIIBRYD, XULTOPHY, XIIDRA... LOTS!

STATUS & REIMBURSEMENT CHANGES

• New generics: AGGRENOX, ATRIPA, ABILIFY, budesonide nebs, CHAMPIX, COVERSYP PLUS, DUOTRAV, FOSFOMYCIN, HP-PC, hydralazine, hydromorphp contm, INSPIRA, LEVITRA, MACROBID, MAVIK, methimazole, perindopril, PRADAXA, RENAGEL, SUBOXONE, TAMIFLU, TROSEC, ULRIC, VIMPAT, VIMOVO, VOLIBRIS, ZELDOX.

• On SK Formulary: BASAGLAR, benztropine 1mg, celecoxib, ciclopirox, clopidogrel, DETROL LA, ENSTILAR, HUMALOG KWIKPEN 200/400, M-EDDAT, KYLEENA, methotrexate SC inj, olanzapine, TRESIBA, TRUVADA, VESICARE

• New EDS: AXERT, BITKARVY, BOTOX, BRILINTA®, BRIVLERA, DUODOPA, DISPORT, DISPORT, EREZL, FASENRA, GLATECH, HEMANGIO, INVEGA TRINZA, KEVZARA, LANCORA, LIAMCA, MICTORAY PEDIATRIC, MOAPO, NUCALA, OCALIVA, OCREVUS, OFESEFY, PRALUENT, REPATHA, PROBUPHINE, PROCYSBI, QUINSAIR, RAVICTI, RENFLIX, REXULTI, SILIQ, STELARA, SYNJARDY, TALTZ, UPTRAVI, VOSVEI

• New full NIH: ADDERAL, AVODART, BASAGLAN, BLANCA, DETROL LA, DTROPAN XL, ENSTILAR, ENSTILORT® EST, EPURIS, JARDIMAGE, JULUCA, KYLEENA, LAMAS for COPD (SPIRIVA, TUDORZA, SEEBRI, INCRUNE), LAMAZ/LABA combo for COPD (DUASKIR, ULITBRO, INSPILOTO, ANORO, methotrexate SC inj, MEZERA, MICTORAY PEDIATRIC, NICORETTE QUICKMIST, OFESEFY, oseltamivir, OZEMPIC, PROSCAR, REXULTI, SYNJARDY, TUJEO, TRESIBA, TRIPLEPTAL, ZOMIG

• New prior NIH approval: ADEMPSA, AFINITOR, ANDRODERM, ANDROGEL, BOSULIF, BRIVLERA, CAYSTON, COLY-MYCIN, COSENTLYX, DIFICID, ENTUVIO, EREZL, ESBRTI, HEMANGIO, IBRANCE, IMBRUVICA, INLYTA, INVEGA TRINZA, JAKAVI, LANCORA, LIAMCA, MARIK, 11 Multiple sclerosis drugs, NUCALA, OCREVUS, PRALUENT, RENFLIX, RENOVA, REPATHA, rotigotine, SILOQ, SIQUA, STRAVGA, TANTUM, TALTZ, TASAAG, tenofovir, TESTIM, UPTRAVI, VOSVEI, XALKORI, XIGDUO

OUTCOME EVIDENCE FROM MAJOR TRIALS

Major outcome trials & drug dosages used are often noted on charts when pertinent. Recently relevant:

CARES (Allopurinol vs febuxostat in gout+CV patients), COMPASS (Rivaroxaban+ASA for 2nd CV prevention), FOURIER (Evolocumab effect on CV events), IMPACT (Trelagliptin vs Brilant in A1c), RE-DUAL PCI (dabigatran+clopidogrel vs triple therapy with warfarin)

SPACE (Oxipid vs nonopioid in Rx of COPD), TARDIS (triple antiplatelet therapy vs standard for stroke), TRUST (levothyroxine in older pts with subclinical hypothyroidism), a VERO (teriparatide vs risedronate in PMO osteoporosis).

RxFiles Drug Comparison Charts

CHART PEARLS

Some of the Guidelines Reviewed

• Cardiovascular: Primary prevention ACC/AHA 19, A, fib AHA 18, CCS 18, CHST 18
  Dyslipidemia ESC 19, AHA 18, Hypertension AHA 18, ESC 18, Hypertension Canada 18

• Diabetes: Treatment Endo Soc 19, ADA 19, Diabetes Canada 18
  Diabetes/Pre-diabetes/CVD ESC 19, A1C targets ACP 18

• Neuro/Psych: Migraine AAN 19, ADHD ACP 19, ACP 19, Parkinson’s Disease, Bipolar Disorder CMACT 18, Alcohol Use Disorder APA 18

• Gastrointestinal: Ulcerative Colitis ACC 18, ACP 18, Crohn’s CAG, ACP 18, IBD ACP 18, IBS CAG 18, Antiemetic ASCO 17

• Infectious Diseases: HPV ACP 18, Cystitis AUA/CSA/ESU 19
  Hepatitis C CASL 18, Vaccines ACP 18, HIV IAS-USA 18, EACS 17, C. diff AMM 18, IDSA 17

• Others: COPD GOLD 19, ETS 19, Beers Criteria AGS 19
  Multiple Sclerosis AAN 18, Erectile Dysfunction AUA 18... etc

RxFiles Academic Detailing
c/o College of Pharmacy and Nutrition
104 Clinic Place, Saskatoon, SK Canada S7N2N4
Tel: (306)906-5972 Fax: (306)906-5387
Email: via our website www.RxFiles.ca
Pregnancy & Lactation Risk Categories

<table>
<thead>
<tr>
<th>PREGNANCY [P]</th>
<th>LACTATION [L]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safe</strong></td>
<td><strong>Safe</strong></td>
</tr>
<tr>
<td>• Compatible in pregnancy</td>
<td>• Compatible in breastfeeding</td>
</tr>
<tr>
<td><strong>Likely Safe</strong></td>
<td><strong>Likely Safe</strong></td>
</tr>
<tr>
<td>• No (limited) human data – probably compatible</td>
<td>• No (limited) human data – probably compatible</td>
</tr>
<tr>
<td>• Compatible: maternal benefit &gt;&gt; embryo-fetal risk</td>
<td></td>
</tr>
<tr>
<td>• Human data suggest low risk</td>
<td></td>
</tr>
<tr>
<td><strong>Caution</strong></td>
<td><strong>Caution</strong></td>
</tr>
<tr>
<td>• Human, and/or animal, data suggest risk</td>
<td>• Hold/delay breastfeeding</td>
</tr>
<tr>
<td>• Potential risk in specific trimester(s), as indicated by ‘x’</td>
<td>• No (limited) human data – potential toxicity</td>
</tr>
<tr>
<td><strong>Contraindicated</strong></td>
<td><strong>Contraindicated</strong></td>
</tr>
<tr>
<td>• Contraindicated in pregnancy</td>
<td>• Contraindicated in breastfeeding</td>
</tr>
<tr>
<td>• Contraindicated in specific trimester(s), as indicated by ‘x’</td>
<td></td>
</tr>
<tr>
<td><strong>Unknown for Pregnancy [P] and/or Lactation [L]</strong></td>
<td></td>
</tr>
<tr>
<td>• No (limited) human data – no relevant animal data</td>
<td></td>
</tr>
</tbody>
</table>

**What you’ll see in the charts:**
- **P** = pregnancy
- **L** = lactation risk category
- Colours correspond to risk categories outlined in this table. Example, warfarin: **P** = contraindicated 1st trimester, **L** = compatible during lactation.